乳腺癌HER-2胞外配体结合区靶点治疗的研究进展  

Research progress on target therapeutic agents of HER-2 extracellular ligand-binding domain in breast cancer

作　　者：钟锦绣(综述)[1] 李亚梅(综述) 关晏星(审校) 

机构地区：[1]南昌大学第一附属医院核医学科,南昌市330006 [2]名西安市妇幼保健院B超室

出　　处：《中国肿瘤临床》2013年第17期1076-1079,共4页Chinese Journal of Clinical Oncology

基　　金：江西省自然科学基金项目(编号:2007GZY1419)资助~~

摘　　要：针对乳腺癌HER-2受体胞外结合区的靶点治疗成为当今研究的热点。小分子多肽、HER-2胞外结合区的单抗药物及其与蛋白毒素、放射性核素,化疗药物的偶联物即免疫偶联物既能增强药物的有效性,又可减少对正常组织的毒害。HER-2胞外区肽疫苗可有效预防HER-2高表达乳腺癌的生长。本文将对乳腺癌HER-2胞外区靶向阻断治疗的研究进行综述,为相应的临床应用提供参考。The target therapeutic agents of HER-2 extracellular ligand-binding domain have become the core of breast cancer research. A small peptide molecule and an anti-HER2 extracellular domain monoclonal antibody conjugated with protein toxins, radioisotopes, and chemotherapeutic drugs （immunoconjugate） can improve efficacy and reduce systemic toxicity. Vaccines based on HER-2 extracellular region should protect patients from HER-2-overexpressing breast cancer growth. In this review, studies on targeted-block therapies of the HER-2 extracellular ligand-binding domain in breast cancer were discussed to provide references for clinical applications.

关 键 词：HER-2乳腺癌 胞外配体结合区 单克隆抗体 抗体偶联物 

分 类 号：R394.4[医药卫生—医学遗传学]